Showing 1121-1130 of 1616 results for "".
- New International Myopia Guidance Urges Early, Personalized Carehttps://modernod.com/news/new-international-myopia-guidance-urges-early-personalized-care/2485288/The International Myopia Institute (IMI) has published its 2025 Digest, delivering the latest evidence-based guidance on myopia. The Dige
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://modernod.com/news/study-targets-early-signs-of-vision-loss-in-diabetic-patients/2482408/The University of Houston (UH) College of Optometry is embarking on a study, backed by a $3.3 million grant from the National Eye Institute, to investigate the progression of vision loss in patients with prediabetes and diabetes. The study, led by Associate Professor Wendy Harrison, aims to ident
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the
- EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-for-yutiq/2476769/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code, J7314, through the Healthcare Common Procedure Coding System (HCPCS) for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micr
- LensGen Will Present Early Results Of International “Grail” Study At ASCRShttps://modernod.com/news/lensgen-will-present-early-results-of-international-grail-study-at-ascrs/2476515/LensGen will share results from its “Grail” study at the ASCRS annual meeting in San Diego, May 3-7. The results will include the latest available data on patients who have been treated at two international sites.
- Study: Ocular Technology Provides Early Detection of Alzheimer’s Diseasehttps://modernod.com/news/study-ocular-technology-provides-early-detection-of-alzheimers-disease/2479626/A recent study from JAMA Ophthalmology finds that a specific type of noninvasive eye testing procedure may help assess risk for Alzheimer’s disease. One in 10 Americans over the age 65 has Alzheimer’s, while one-third over the age of 85 have the disease. Fortunately, res
- Eye Testing May Aid Early Diagnosis of Creutzfeldt-Jakob Diseasehttps://modernod.com/news/eye-testing-may-aid-early-diagnosis-of-creutzfeldt-jakob-disease/2479629/Eye examinations may aid clinicians in the diagnosis of sporadic Creutzfeldt-Jacob disease (sCJD), results of a small postmortem study show, according to a report in Medscape. In an evaluation of the eyes and brains of 11 sCJD pati
- Evidence Mounts That an Eye Scan May Detect Early Alzheimer’s Diseasehttps://modernod.com/news/evidence-mounts-that-an-eye-scan-may-detect-early-alzheimers-disease/2479725/Results from two studies show that a new, non-invasive imaging device can see signs of Alzheimer’s disease in a matter of seconds. The researchers show that the small blood vessels in the retina at the back of the eye are altered in patients with Alzheimer’s. Even patients who have a family histo
- Aerie Pharmaceuticals Announces Early Notification of FDA Acceptance of NDA Submission for Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-early-notification-of-fda-acceptance-of-nda-submission-for-roclatan/2479999/Aerie Pharmaceuticals reported that it has received the “Day 74” notification from the FDA earlier than scheduled. The FDA has completed its initial 60-day review of the new drug application (NDA) for Roclatan (netarsudil/latanoprostnetarsudil ophthalmic solution) 0.02%/0.005% and the FDA has det